Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 345

Similar articles for PubMed (Select 11305706)

1.

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S.

J Clin Psychiatry. 2001 Mar;62(3):191-8.

PMID:
11305706
2.

Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.

Czekalla J, Kollack-Walker S, Beasley CM Jr.

J Clin Psychiatry. 2001;62 Suppl 2:35-40. Review.

PMID:
11232751
4.

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.

Lindborg SR, Beasley CM, Alaka K, Taylor CC.

Psychiatry Res. 2003 Jul 15;119(1-2):113-23.

PMID:
12860365
5.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
6.

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A.

J Sex Marital Ther. 2003 Mar-Apr;29(2):125-47.

PMID:
12623765
8.

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P.

Arch Gen Psychiatry. 2002 May;59(5):441-8.

PMID:
11982448
9.

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O'Gorman C, Harrigan RH.

Clin Ther. 2010 Mar;32(3):472-91. doi: 10.1016/j.clinthera.2010.03.003.

PMID:
20399985
10.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Apr;62(4):231-8.

PMID:
11379836
11.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
12.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
13.

Novel antipsychotics: comparison of weight gain liabilities.

Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR.

J Clin Psychiatry. 1999 Jun;60(6):358-63.

PMID:
10401912
14.

Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.

Camm AJ, Karayal ON, Meltzer H, Kolluri S, O'Gorman C, Miceli J, Tensfeldt T, Kane JM.

CNS Drugs. 2012 Apr 1;26(4):351-65. doi: 10.2165/11599010-000000000-00000.

PMID:
22452529
15.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
16.
17.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
18.

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.

Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH.

Am J Psychiatry. 1997 Sep;154(9):1248-54.

PMID:
9286184
19.

Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.

Sauriol L, Laporta M, Edwardes MD, Deslandes M, Ricard N, Suissa S.

Clin Ther. 2001 Jun;23(6):942-56.

PMID:
11440294
20.

Antipsychotic drugs and QT interval prolongation.

Zareba W, Lin DA.

Psychiatr Q. 2003 Fall;74(3):291-306. Review.

PMID:
12918603
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk